Sign Up
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Nuvaxovid 2025-2026 Formula COVID-19 vaccine approved in the U.S – Novavax

Written by | 14 Sep 2025 | COVID-19

Novavax, Inc. announced that the FDA has approved the Nuvaxovid 2025-2026 Formula for the prevention of COVID-19 in individuals 65 years of age and older, or 12 years – 64 years of age with at least one underlying condition that puts them at high risk for severe outcomes from COVID-19. Clinical and preclinical data have previously shown that Nuvaxovid is safe and effective for the prevention of COVID-19.

(See citations) Both clinical and preclinical data from Nuvaxovid confirm that the JN.1 strain vaccination induces immunity across currently circulating JN.1 lineage strains, including NB.1.8.1, LP.8.1, XFG, XFC, LF.7 and XEC. As of July 2025, the vast majority of COVID-19 infections globally are caused by variants within the JN.1 strain.

Sanofi is leading commercialization efforts for Nuvaxovid and Novavax is eligible to receive ongoing tiered royalties from sales of the vaccine.

Newsletter Icon

Register for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.

Sign Up

You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.